{"id":"W2558690325","doi":"10.1093/neuonc/now212.068","title":"ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA","year":2016,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Interim analysis; Temozolomide; Hazard ratio; Internal medicine; Oncology; Cohort; Clinical endpoint; Confidence interval; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001087052,0.001906776,0.00166742,0.0006395626,0.0003884546,0.0009901272,0.001090993,0.001317801,0.004906917],"category_scores_gemma":[0.0005806172,0.0005210171,0.001308838,0.0004227925,0.0008430479,0.0006739217,0.0002816442,0.003171554,0.001368318],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000814537,"about_ca_system_score_gemma":0.001463748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001117932,"about_ca_topic_score_gemma":0.002601488,"domain_scores_codex":[0.999744,0.0001092509,0.00001093858,0.00004292805,0.00001888568,0.00007403734],"domain_scores_gemma":[0.9997202,0.00004245768,0.00005455891,0.00002534978,0.00001909466,0.0001383366],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8397313,0.03065372,0.001314323,0.00108186,0.001035362,0.0001522649,0.0001827271,0.001796499,0.02428158,0.0007895062,0.009842736,0.08913811],"study_design_scores_gemma":[0.8630733,0.1271777,0.00257815,0.00004093044,0.0002841357,0.0001408397,0.00002845408,0.0009653777,0.002438735,0.0003957575,0.002847261,0.00002920706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9724629,0.005847022,0.001705162,0.001126788,0.0006090433,0.006297969,0.003823364,0.0009424812,0.007185211],"genre_scores_gemma":[0.9679252,0.00354836,0.003521267,0.002696972,0.0003217217,0.008314193,0.004507675,0.0001038766,0.009060695],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004906917,"threshold_uncertainty_score":0.0164153,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05272591588098204,"score_gpt":0.3763128567312981,"score_spread":0.323586940850316,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}